Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19625786 | 1.00 | LMNA (0.50) | LMNAMEN1KMT2AHTTPTPN1 | |
| SCHEMBL17865779 | 0.89 | LMNA (0.58) | LMNAHTTMAOBAOC3 | |
| SCHEMBL24554348 | 0.84 | MEN1 (0.47) | MEN1KMT2AHTTPTPN1CES2 | |
| SCHEMBL1233194 | 0.84 | MEN1 (0.47) | MEN1KMT2AHTTPTPN1CES2 | |
| SCHEMBL2522600 | 0.83 | LMNA (0.53) | LMNAKMT2AHTTMAOBAOC3 | |
| SCHEMBL1742088 | 0.82 | EGLN1 (0.50) | MEN1KMT2APTPN1CES2CES1 | |
| SCHEMBL14009645 | 0.82 | MAOB (0.65) | LMNAMEN1KMT2AHTTMAOB | |
| SCHEMBL7753604 | 0.82 | TRPV1 (0.59) | LMNAHTTPTPN1CES2CES1 | |
| SCHEMBL3757683 | 0.81 | NPC1 (0.52) | MEN1KMT2APTPN1NPC1RAB9A | |
| SCHEMBL12206267 | 0.81 | KCNN4 (0.48) | MEN1KMT2APTPN1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1034783-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS | SUMITOMO PHARMA (JP) | 2004-12-15 | — | — | EP | claimed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | claimed |
| EP-1034783-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | claimed |
| CN-119192012-A | Reductive amidation method of aryl fluorosulfonate and isocyanate | 南京工业大学 | 2024-12-27 | — | — | CN | disclosed |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| US-20220194930-A1 | Matrix Metalloproteinase Inhibitors and Imaging Agents, And Methods Using Same | UNIV YALE (US) | 2022-06-23 | — | — | US | disclosed |
| CN-113620761-B | Preparation method for synthesizing aryl aldehyde compound by reducing aryl secondary amide or aryl secondary amide derivative with phenylsilane | 西北工业大学 | 2022-06-17 | — | — | CN | disclosed |
| CN-113620761-A | Preparation method for synthesizing aryl aldehyde compound by reducing aryl secondary amide or aryl secondary amide derivative with phenylsilane | 西北工业大学 | 2021-11-09 | — | — | CN | disclosed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-10968199-B2 | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200283428-A1 | Matrix Metalloproteinase Inhibitors and Imaging Agents, And Methods Using Same | YALE UNIVERSITY | 2020-09-10 | — | — | US | disclosed |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | METHYLGENE INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| US-20070149556-A1 | Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
| US-6936736-B2 | Amide derivative | SUMITOMO MANUFACTURING COMPANY LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1034783-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS | SUMITOMO PHARMA (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1184367-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-03-06 | — | — | EP | disclosed |
| EP-1034783-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
| US-5563144-A | SERATONIN ANTAGONISTS FOR TREATMENT OF DISORDERS OF CENTRAL NERVOUS, CARDIOVASCULAR AND GASTROINTESTINAL SYSTEMS | RHONE-POULENC RORER S.A. (FR) | 1996-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | LMNA 4771/4885MEN1 2023/4885KMT2A 2115/4885 |
| US-20070149556-A1 | Hydroxypyrimidinone derivatives having inhibitory activity against hiv integrase | HAT1, SULT1A1, CDK20 | LMNA 3192/4885MEN1 4651/4885KMT2A 1167/4885 |
| US-20200283428-A1 | Matrix Metalloproteinase Inhibitors and Imaging Agents, And Methods Using Same | MMP1, MMP3, TIMP3 | LMNA 796/4885MEN1 322/4885KMT2A 3234/4885 |
| US-10968199-B2 | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | BAD, BCL2, AIFM1 | LMNA 2011/4885MEN1 4743/4885KMT2A 3618/4885 |
| US-20220194930-A1 | Matrix Metalloproteinase Inhibitors and Imaging Agents, And Methods Using Same | MMP3, MMP1, MMP10 | LMNA 927/4885MEN1 450/4885KMT2A 2836/4885 |
| US-20070293530-A1 | SULFAMIDE AND SULFAMATE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HAT1 | LMNA 2203/4885MEN1 3832/4885KMT2A 37/4885 |
| US-20020147204-A1 | Amide derivative | ALDH1A2, NR1H2, HDAC3 | LMNA 2807/4885MEN1 3899/4885KMT2A 1003/4885 |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | SIGMAR1, TMEM97, OPRM1 | LMNA 4760/4885MEN1 4146/4885KMT2A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.